Non-Viral Transfection Reagents Market
授權報價
| Single User | $4,799 USD |
| Multi User | $7,999 USD |
| Enterprise / Global Site Licence | $17,999 USD |
完整報告名稱與涵蓋範圍
Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035
報告摘要
NON-VIRAL TRANSFECTION REAGENTS MARKET: OVERVIEW
As per Roots Analysis, the global non-viral transfection reagents market is estimated to grow from 0.89 billion in the current year to USD 2.01 billion by 2035, at a CAGR of 9.5% during the forecast period, till 2035.
NON-VIRAL TRANSFECTION REAGENTS MARKET: GROWTH AND TRENDS
Nucleic acid-based therapies have demonstrated significant potential in targeting genetic mechanisms for the treatment of a broad range of therapeutic indications. Consequently, a growing number of these therapies have secured regulatory approvals, underscoring both their clinical potential and the increasing adoption of this therapeutic class.
The expanding pipeline and commercialization of nucleic acid-based therapeutics have accelerated the demand for efficient delivery platforms capable of ensuring targeted and effective intracellular delivery. Traditionally, the development and manufacturing of such therapies have relied heavily on viral vectors. However, despite substantial advancements in viral vector research and manufacturing capabilities, several limitations continue to hinder their widespread applicability.
Key challenges associated with viral vectors include immunogenicity and cytotoxicity concerns, high development and manufacturing costs, and limitations related to the quantity of genetic material that can be delivered per dose. In response to these constraints, industry stakeholders are increasingly transitioning toward non-viral gene delivery technologies for transfection applications.
Non-viral transfection systems involve the targeted delivery of genetic material into a diverse range of cell types using non-viral vectors as delivery carriers. To address the growing demand for nucleic acid-based therapeutics, companies are actively developing advanced non-viral transfection reagents and systems that are highly suitable for in vitro intracellular delivery applications. Furthermore, driven by the rising preference for non-viral vectors and ongoing technological advancements in transfection reagents and systems, the non-viral transfection reagents market is anticipated to witness steady growth in the coming years.
Growth Drivers: Strategic Enablers of Market Expansion
The non-viral transfection reagents market is primarily driven by the growing demand for nucleic acid-based therapeutics, including gene therapies, mRNA therapeutics, RNAi-based drugs, and DNA vaccines, which require efficient intracellular delivery technologies. In addition, the limitations associated with viral vectors, such as immunogenicity, cytotoxicity, high manufacturing costs, and limited cargo capacity, are encouraging the adoption of non-viral delivery systems as safer and more scalable alternatives. The market is further supported by increasing research activities in cell and gene therapy, rising investments in biotechnology and pharmaceutical R&D, and the expanding adoption of gene editing technologies such as CRISPR-Cas9. Moreover, continuous technological advancements in lipid-based, polymer-based, and nanoparticle-based transfection systems have enhanced delivery efficiency and cell viability, thereby accelerating market adoption across research and therapeutic applications.
Market Challenges: Critical Barriers Impeding Progress
The non-viral transfection reagents market faces several challenges despite its growing adoption across research and therapeutic applications. One of the primary concerns is the relatively lower transfection efficiency of non-viral systems compared to viral vectors, particularly in hard-to-transfect and primary cell types. In addition, issues related to limited intracellular uptake, reduced stability of genetic material, transient gene expression, and potential cytotoxic effects of certain reagents continue to hinder widespread application. The lack of standardized protocols and variability in transfection performance across different cell lines further complicate product adoption in both research and clinical settings. Moreover, the development of highly efficient and targeted non-viral delivery systems requires substantial investment in research and optimization, increasing overall development costs. Regulatory complexities associated with advanced gene delivery technologies and the growing competition from emerging delivery platforms also pose significant challenges to market growth.
NON-VIRAL TRANSFECTION REAGENTS MARKET: KEY TRENDS
The report delves into the current state of the non-viral transfection reagents market and identifies potential growth opportunities within industry. Some key highlights in this domain include:
Rising Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases has accelerated the demand for innovative and potentially curative therapeutic interventions, thereby driving the adoption of non-viral transfection reagents and systems. The growing preference for non-viral transfection technologies can be attributed to the multiple advantages they offer, including enhanced therapeutic efficacy through targeted and localized delivery while minimizing systemic exposure. As a result, these technologies have the potential to improve treatment outcomes and enhance patient quality of life across various therapeutic applications.
Advancements in Nanotechnology and Biotechnology: Continuous advancements in nanotechnology and biotechnology have enabled the developers to improve drug efficacy and delivery precision. Advanced nanomaterials facilitate targeted intracellular delivery while reducing systemic side effects, owing to their multifunctional design capabilities that allow the incorporation of targeting ligands and therapeutic payloads. Several non-viral transfection reagents leveraging nanotechnology-based delivery carriers have emerged in the market, including products such as jetOPTIMUS and PolyMag.
Non-Viral Transfection Reagents Market
The market sizing and opportunity analysis has been segmented across the following parameters:
Market by Type of Non-Viral Transfection Method
• Chemical Methods
• Physical Methods
• Other Methods
Market by Application Area
• Research Applications
• Clinical Applications
Market by End-User
• Veterinary Academic and Research Institutions
• Pharmaceutical and Biotechnological Companies
• Contract Manufacturers
• Other End-users
Market by Geographical Regions
• North America
• US
• Canada
• Europe
• France
• Germany
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• Australia
• South Korea
• China
• Rest of Asia-Pacific
• Middle East and Africa
• Saudi Arabia
• UAE
• Egypt
• Rest of Middle East and Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America
NON-VIRAL TRANSFECTION REAGENTS MARKET: KEY SEGMENTS
Which Type of Non-Viral Transfection Method Accounts for the Largest Share of the Non-Viral Transfection Reagents and Equipment Market?
The non-viral transfection reagents and equipment market is segmented based on the type of non-viral transfection method into chemical methods, physical methods, and other methods. According to the non-viral transfection reagents market analysis, the chemical methods segment captures nearly 60% of the overall market share. This dominance can be attributed to the increasing adoption of primary cell transfection reagents and non-viral vectors in gene therapy applications across the global market.
The physical methods segment is anticipated to witness a comparatively higher CAGR during the forecast period, driven by ongoing technological advancements in techniques such as electroporation. These technologies offer several advantages, including shorter transfection timelines, improved biological efficiency, lower toxicity, and enhanced versatility for nucleic acid delivery across a broad range of cell types.
Regional Analysis: Which Regions are Demonstrating the Fastest Growth in the Non-Viral Transfection Reagents Industry?
North America: Largest Regional Market
North America represents approximately 60% of the global non-viral transfection reagents market share. The region’s leadership position is supported by its well-established pharmaceutical and biotechnology industry, coupled with the rapid adoption of advanced non-viral transfection technologies. Moreover, North America serves as a major hub for companies involved in the development of complex biologics and advanced therapeutics, including cell and gene therapies, thereby generating significant demand for locally manufactured non-viral transfection reagents and systems, particularly due to their limited shelf life and specialized handling requirements.
US Non-Viral Transfection Reagents Market Trends
In the US, supportive regulatory pathways established by the US Food and Drug Administration for the approval of DNA transfection reagents, RNA transfection reagents, and non-viral transfection technologies are contributing significantly to market growth. Although regulatory standards remain stringent, the availability of clear regulatory guidance for validation and commercialization has facilitated broader adoption and accelerated market entry for innovative transfection systems.
Asia-Pacific: Emerging as a Key Growth Hub
The Asia-Pacific non-viral transfection reagents market is anticipated to witness the highest CAGR through 2035. This growth is primarily driven by the region’s expanding large-scale manufacturing capabilities for active pharmaceutical ingredients (APIs) and the increasing outsourcing of high-value biologics manufacturing activities. In order to comply with global quality and export standards, regional manufacturers are making significant investments in advanced manufacturing infrastructure and increasingly adopting non-viral transfection reagents and systems across research and production workflows.
Will the Research Applications Segment Continue to Hold the Largest Market Share?
According to the non-viral transfection reagents market forecast, the research applications segment currently represents the largest share of the market. This dominance can be attributed to the growing focus on research and development activities, along with the increasing adoption of non-viral transfection methods across molecular biology, cell biology, and gene therapy research applications. Meanwhile, the clinical applications segment is expected to register a higher CAGR during the forecast period. The rising prevalence of chronic diseases, coupled with the increasing number of approvals for cell and gene therapies, is anticipated to drive the growth of this segment over the coming years.
Primary Research Overview
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
• Former-Vice-President, Business Development and Partnerships, Small Company, US
• Former Global Business Development Manager, Clinical Operations, Mid-sized Company, France
• Researcher, Mid-sized Non-Industry Player, Chile
Additionally, the market report includes transcripts of the following third-party discussions:
• Chairman and Chief Executive Officer, Mid-sized Company, the US
• Co-Founder and Chief Executive Officer, Small Company, the US
• Chief Scientific Officer and Executive Vice President of R&D, Mid-sized Company, the US
• Chief Scientific Officer, Mid-sized Company, the US
• Vice President of Cell Therapy Process Development, Large Company, the US
• Group Leader of R&D Transfection, and Director and Senior Product Manager, Large Company, Switzerland
Example Players in Non-Viral Transfection Reagents Market
• BEX
• Bio-Rad Laboratories
• Harvard Bioscience
• LocateBio
• MaxCyte
• MilliporeSigma
• Nepa Gene
• N4 Pharma
• OZ Biosciences
• Thermo Fisher Scientific
NON-VIRAL TRANSFECTION REAGENTS MARKET: RESEARCH COVERAGE
• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global non-viral transfection reagents market, focusing on key market segments, including [A] type of non-viral transfection method, [B] application area, [C] end-user and [D] key geographical regions.
• Non-Viral Transfection Reagents Market Landscape: A comprehensive evaluation of the companies developing non-viral transfection reagents, based on several relevant parameters, such as [A] type of carrier used, [B] compatible cell type, [C] type of molecule delivered and [D] serum compatibility. Additionally, a comprehensive evaluation of non-viral transfection reagent developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Electroporation-Based Transfection Systems Market Landscape: A detailed analysis of the companies developing electroporation-based non-viral transfection systems, based on several relevant parameters, such as [A] compatible cell type and [B] type of molecule delivered. Additionally, a comprehensive evaluation of electroporation transfection systems developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Other Non-Viral Transfection Systems Market Landscape: An insightful evaluation of the companies developing other non-viral transfection systems, based on several relevant parameters, such as [A] compatible cell type and [B] type of molecule delivered. Additionally, a comprehensive evaluation of other non-viral transfection systems developers, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
• Company Competitiveness Analysis: A comprehensive competitive analysis of non-viral transfection reagent and system developers, examining factors, such as [A] developer strength and [B] product portfolio strength.
• Technology Competitiveness Analysis: A detailed analysis of electroporation transfection systems and other non-viral transfection systems, examining factors, such as [A] developer strength and [B] product portfolio strength.
• Company Profiles: In-depth profiles of key players that are engaged in the development of non-viral transfection reagents and systems, focusing on [A] overview of the company, [B] financial information (if available) and [C] recent developments and an informed future outlook.
• Potential Strategic Partners: An insightful analysis of more than 80 cell and gene therapy developers that are likely to partner with non-viral transfection reagent and system developers, based on several relevant parameters, such as [A] pipeline maturity, [B] developer strength, [C] pipeline strength and [D] type of therapy.
• Benchmark Analysis: A comprehensive benchmark analysis of various non-viral focused initiatives undertaken by big pharma players, based on several relevant parameters, such as [A] year of initiative, [B] type of initiative, [C] type of therapy and [D] target therapeutic area.
• Patent Analysis: An in-depth analysis of patents filed / granted till date in the non-viral transfection systems domain, based on various relevant parameters, such as [A] type of patent, [B] publication year, [C] application year, [D] geography, [E] type of applicant, [F] CPC symbols, [G] emerging focus areas, [H] leading players (in terms of number of patents granted / filed), [I] patent benchmarking and [J] valuation analysis.
• Publication Analysis: An insightful analysis of over 450 peer-reviewed, scientific articles focused on non-viral transfection reagents and systems, based on various relevant parameters, such as [A] year of publication, [B] type of publication, [C] type of molecule delivered, [D] target therapeutic area, [E] key focus areas, [F] popular cells and cell lines. Additionally, the section includes analysis of the leading publishers across different geographies and key journals (in terms of number of articles published).
• Roots Analysis Pricing Strategy Framework: A detailed framework for analyzing the pricing strategy of a company's non-viral transfection reagents and its competitive market position, including an equation to estimate reagent prices based on their characteristics.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.
KEY QUESTIONS ANSWERED IN THIS REPORT
• Which are the leading companies in the non-viral transfection reagents market?
• Which region dominates the non-viral transfection reagents market?
• What are the key trends observed in non-viral transfection reagents market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by non-viral transfection reagents providers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.
ADDITIONAL BENEFITS
• Complementary PPT Insights Pack
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older
目錄 Table of Contents
1. PREFACE
1.1. Introduction
1.2. Report Coverage
1.3. Market Segmentation
1.4. Key Market Insights
1.5. Market Share Insights
1.6. Key Questions Asked
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Chapter Overview
6.2. Introduction to Transfection
6.3. Methods of Transfection
6.3.1. Virus Based Transfection
6.3.1.1. Types of Viral Transfection Vectors
6.3.1.1.1. Adeno-associated Virus-based Vectors
6.3.1.1.2. Adenovirus-based Vectors
6.3.1.1.3. Herpes Virus-based Vectors
6.3.1.1.4. Lentivirus-based Vectors
6.3.1.1.5. Retrovirus-based Vectors
6.3.2. Non-Virus Based Transfections
6.3.2.1. Chemical Methods based Transfection
6.3.2.1.1. Lipoplexes-based Transfection
6.3.2.1.2. Polyplexes-based Transfection
6.3.2.1.3. Lipo-polyplexes-based Transfection
6.3.2.1.4. Dendrimer-based Transfection
6.3.2.1.5. Cell Penetrating Peptide-based Transfection
6.3.2.2. Physical Method based Transfections
6.3.2.2.1. Electroporation-based Transfection
6.3.2.2.2. Gene Gun-based Transfection
6.3.2.2.3. Sonoporation-based Transfection
6.3.2.2.4. Microinjection-based Transfection
6.3.2.2.5. Magnetofection-based Transfection
6.4. Applications of Transfection
6.4.1. Advanced Therapeutic Medicinal Product Development
6.4.2. Gene Silencing
6.4.3. Generation of Stable Cell Lines
6.4.4. Large-scale Protein Production
6.4.5. Stem Cell Engineering
6.5. Future Perspective
7. MARKET LANDSCAPE: NON-VIRAL TRANSFECTION REAGENTS
7.1. Chapter Overview
7.2. Non-Viral Transfection Reagents: Overall Market Landscape
7.2.1. Analysis by Compatible Cell Type / Line
7.2.2. Analysis by Transfected Molecule
7.2.3. Analysis by Type of Transfection Carrier Used
7.2.4. Analysis by Type of Cell Culture
7.2.5. Analysis by Serum Compatibility
7.3. Non-Viral Transfection Reagent Providers Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
8. MARKET LANDSCAPE: ELECTROPORATION-BASED TRANSFECTION SYSTEMS
8.1. Chapter Overview
8.2. Electroporation-based Transfection Systems: Overall Market Landscape
8.2.1. Analysis by Compatible Cell Type / Line
8.2.2. Analysis by Transfected Molecule
8.2.3. Analysis by Type of Waveform
8.2.4. Analysis by Pulse Voltage
8.3. Electroporation-based Transfection System Providers Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Analysis by Leading Players
9. MARKET LANDSCAPE: OTHER NON-VIRAL TRANSFECTION TECHNOLOGIES / SYSTEMS
9.1. Chapter Overview
9.2. Other Non-Viral Transfection Technologies / Systems: Market Landscape
9.2.1. Analysis by Type of Offering
9.2.2. Analysis by Compatible Cell Type / Line
9.2.3. Analysis by Transfected Molecule
9.3. Other Non-Viral Transfection Technologies / System Providers Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
10. COMPANY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Company Competitiveness Analysis: Non-Viral Transfection Reagent Providers
10.4.1. Non-Viral Transfection Reagent Providers based in North America (Peer Group I)
10.4.2. Non-Viral Transfection Reagent Providers based in Europe (Peer Group II)
10.4.3. Non-Viral Transfection Reagent Providers based in Asia-Pacific (Peer Group III)
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Technology Competitiveness Analysis: Electroporation-based Transfection Systems
11.4.1. Electroporation-based Transfection Systems Offered by Players based in North America (Peer Group I)
11.4.2. Electroporation-based Transfection Systems Offered by Players based in Europe and Asia-Pacific (Peer Group II)
11.5. Technology Competitiveness Analysis: Other Non-Viral Transfection Technology / Systems
11.5.1. Other Non-Viral Transfection Technologies / Systems Offered by Players based in North America (Peer Group I)
11.5.2. Other Non-Viral Transfection Technologies / Systems Offered by Players based in Europe and Asia-Pacific (Peer Group II)
12. COMPANY PROFILES
12.1. Chapter Overview
12.2. Non-Viral Transfection Reagent Providers
12.2.1. MilliporeSigma
12.2.1.1. Company Overview
12.2.1.2. Financial Information
12.2.1.3. Non-Viral Transfection Reagents Portfolio
12.2.1.4. Recent Developments and Future Outlook
12.2.2. OZ Biosciences
12.2.2.1. Company Overview
12.2.2.2. Non-Viral Transfection Reagents Portfolio
12.2.2.3. Recent Developments and Future Outlook
12.2.3. Thermo Fisher Scientific
12.2.3.1. Company Overview
12.2.3.2. Financial Information
12.2.3.3. Non-Viral Transfection Reagents Portfolio
12.2.3.4. Recent Development and Future Outlook
12.3. Electroporation-based Non-Viral Transfection System Providers
12.3.1. BEX
12.3.1.1. Company Overview
12.3.1.2. Electroporation-based Non-Viral Transfection System Portfolio
12.3.1.3. Recent Developments and Future Outlook
12.3.2. Bio-Rad Laboratories
12.3.2.1. Company Overview
12.3.2.2. Financial Information
12.3.2.3. Electroporation-based Non-Viral Transfection System Portfolio
12.3.2.4. Recent Developments and Future Outlook
12.3.3. Harvard Bioscience
12.3.3.1. Company Overview
12.3.3.2. Financial Information
12.3.3.3. Electroporation-based Non-Viral Transfection System Portfolio
12.3.3.4. Recent Developments and Future Outlook
12.3.4. MaxCyte
12.3.4.1. Company Overview
12.3.4.2. Financial Information
12.3.4.3. Electroporation-based Non-Viral Transfection System Portfolio
12.3.4.4. Recent Developments and Future Outlook
12.3.5. NepaGene
12.3.5.1. Company Overview
12.3.5.2. Electroporation-based Non-Viral Transfection System Portfolio
12.3.5.3. Recent Developments and Future Outlook
12.4. Other Non-Viral Transfection Technology / System Providers
12.4.1. LocateBio
12.4.1.1. Company Overview
12.4.1.2. Other Non-Viral Transfection Technology / System Portfolio
12.4.1.3. Recent Developments and Future Outlook
12.4.2. N4 Pharma
12.4.2.1. Company Overview
12.4.2.2. Other Non-Viral Transfection Technology / System Portfolio
12.4.2.3. Recent Developments and Future Outlook
13. POTENTIAL STRATEGIC PARTNERS
13.1. Chapter Overview
13.2. Assumptions and Key Parameters
13.3. Scope and Methodology
13.4. Potential Strategic Partners for Non-Viral Transfection Reagents and Systems Providers based in North America
13.4.1. Most Likely Partners
13.4.2. Likely Partners
13.4.3. Less Likely Partners
13.4.4. Least Likely Partners
13.5. Potential Strategic Partners for Non-Viral Transfection Reagents and Systems Providers based in Europe
13.5.1. Most Likely Partners
13.5.2. Likely Partners
13.5.3. Less Likely Partners
13.5.4. Least Likely Partners
13.6. Potential Strategic Partners for Non-Viral Transfection Reagents and Systems Providers based in Asia-Pacific and Rest of the World
13.6.1. Most Likely Partners
13.6.2. Likely Partners
13.6.3. Less Likely Partners
13.6.4. Least Likely Partners
14. MARKET TRENDS ANALYSIS
14.1. Chapter Overview
14.2. Ex-vivo and In-vivo Therapy Trends
14.3. Viral and Non-Viral Vector Trends
15. PATENT ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Non-Viral Transfection: Patent Analysis
15.3.1. Analysis by Patent Publication Year
15.3.2. Analysis by Type of Patent and Publication Year
15.3.3. Analysis by Patent Application Year
15.3.4. Analysis by Patent Jurisdiction
15.3.5. Analysis by CPC Symbols
15.3.6. Analysis by Type of Applicant
15.3.7. Leading Players: Analysis by Number of Patents
15.3.8. Leading Inventors: Analysis by Number of Patents
15.4. Patent Benchmarking Analysis
15.4.1. Analysis by Patent Characteristics
15.5. Patent Valuation
16. PUBLICATION ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Non-Viral Transfection Reagents and Systems: Publication Analysis
16.3.1. Analysis by Year of Publication
16.3.2. Most Active Publisher: Analysis by Number of Publications
16.3.3. Key Journals: Analysis by Journal Impact Factor
16.3.4. Most Popular Journals: Analysis by Number of Publications
16.4. Prominent Copyright Holders: Analysis by Number of Publications
17. ROOTS ANALYSIS PRICING STRATEGY FRAMEWORK
17.1. Chapter Overview
17.2. Roots Analysis Framework
17.2.1. Methodology
17.2.2. Theoretical Framework and Price Evaluation Hypothesis
17.2.3. Results and Interpretation
17.2.3.1. Product Price Evaluation Matrix: Based on Transfection Efficiency
17.2.3.2. Product Price Evaluation Matrix: Based on Compatible Cell Type / Line
17.2.3.3. Product Price Evaluation Matrix: Based on Type of Carrier Used
17.2.3.4. Product Price Evaluation Matrix: Based on Type of Molecule Delivered
17.2.3.5. Product Price Evaluation Matrix: Based on Type of Reagent
17.3. Concluding Remarks
18. MARKET IMPACT ANALYSIS
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
19. GLOBAL NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Global Non-Viral Transfection Reagents and Systems Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations
20. NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY TYPE OF TRANSFECTION METHOD
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Non-Viral Transfection Reagents and Systems Market: Distribution by Type of Transfection Method
20.3.1. Non-Viral Transfection Reagents and Systems Market for Chemical Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.2. Non-Viral Transfection Reagents and Systems Market for Physical Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.3. Non-Viral Transfection Reagents and Systems Market for Other Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation
21. NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY APPLICATION AREA
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Non-Viral Transfection Reagents and Systems Market: Distribution by Application Area
21.3.1. Non-Viral Transfection Reagents and Systems Market for Research Applications, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.2. Non-Viral Transfection Reagents and Systems Market for Clinical Applications, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation
22. NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY END-USER
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Non-Viral Transfection Reagents and Systems Market: Distribution by End-User
22.3.1. Non-Viral Transfection Reagents and Systems Market for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.3.2. Non-Viral Transfection Reagents and Systems Market for Pharmaceutical and Biopharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.3.3. Non-Viral Transfection Reagents and Systems Market for Contract Manufacturers, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.3.4. Non-Viral Transfection Reagents and Systems Market for Other End-Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. NON-VIRAL TRANSFECTION REAGENTS AND SYSTEMS MARKET, BY KEY GEOGRAPHICAL REGIONS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Non-Viral Transfection Reagents and Systems Market: Distribution by Geographical Regions
23.3.1. Non-Viral Transfection Reagents and Systems Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.1.1. Non-Viral Transfection Reagents and Systems Market in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.1.2. Non-Viral Transfection Reagents and Systems Market in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.2. Non-Viral Transfection Reagents and Systems Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.2.1. Non-Viral Transfection Reagents and Systems Market in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.2.2. Non-Viral Transfection Reagents and Systems Market in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.2.3. Non-Viral Transfection Reagents and Systems Market in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.2.4. Non-Viral Transfection Reagents and Systems Market in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.2.5. Non-Viral Transfection Reagents and Systems Market in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.2.6. Non-Viral Transfection Reagents and Systems Market in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.3. Non-Viral Transfection Reagents and Systems Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.3.1. Non-Viral Transfection Reagents and Systems Market in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.3.2. Non-Viral Transfection Reagents and Systems Market in Australia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.3.3. Non-Viral Transfection Reagents and Systems Market in South Korea, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.3.4. Non-Viral Transfection Reagents and Systems Market in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.3.5. Non-Viral Transfection Reagents and Systems Market in Rest of Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.4. Non-Viral Transfection Reagents and Systems Market in Middle East and Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.4.1. Non-Viral Transfection Reagents and Systems Market in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.4.2. Non-Viral Transfection Reagents and Systems Market in UAE, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.4.3. Non-Viral Transfection Reagents and Systems Market in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.4.4. Non-Viral Transfection Reagents and Systems Market in Rest of Middle East and Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.5. Non-Viral Transfection Reagents and Systems Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.5.1. Non-Viral Transfection Reagents and Systems Market in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.5.2. Non-Viral Transfection Reagents and Systems Market in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.5.3. Non-Viral Transfection Reagents and Systems Market in Rest of Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.4. Market Dynamics Assessment
23.4.1. Market Movement Analysis
23.4.2. Penetration-Growth (P-G) Matrix
23.5. Data Triangulation and Validation
24. CONCLUDING REMARKS
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Company A
25.2.1. Interview Transcript: Former Vice President, Business Development and Partnerships
25.3. Company B
25.3.1. Interview Transcript: Former Global Business Development Manager, Clinical Operations
25.4. Company C
25.4.1. Interview Transcript: Researcher
26. APPENDIX I: TABULATED DATA
27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
圖表清單 List of Tables & Figures
Table 3.1 Specifications of Viral Vectors
Table 7.1 Non-Viral Transfection Reagents: Information on Compatible Cell Type / Line and Volume of Reagent (per unit DNA / RNA)
Table 7.2 Non-Viral Transfection Reagents: Information on Transfected Molecule and Type of Transfection Carrier Used
Table 7.3 Non-Viral Transfection Reagents: Information on Type of Cell Culture and Serum Compatibility
Table 7.4 Non-Viral Transfection Reagents: List of Providers
Table 8.1 Electroporation-based Transfection Systems: Information on Compatible Cell Type / Line and Transfected Molecule
Table 8.2 Electroporation-based Transfection Systems: Information on Type of Waveform and Pulse Voltage
Table 8.3 Electroporation-based Transfection Systems: Information on Pulse Time, Efficiency, Cell Viability and Reaction Time
Table 8.4 Electroporation-based Transfection Systems: List of Providers
Table 9.1 Other Non-Viral Transfection Systems: Information on Type of Offering, Compatible Cell Type / Line, and Transfected Molecule
Table 9.2 Other Non-Viral Transfection Technology / System Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 12.1 List of Non-viral Transfection Reagents, Systems, and Technology Providers Profiled
Table 12.2 MilliporeSigma: Company Overview
Table 12.3 MilliporeSigma: Non-viral Transfection Reagents Portfolio
Table 12.4 MilliporeSigma: Recent Developments and Future Outlook
Table 12.5 OZ Biosciences: Company Overview
Table 12.6 OZ Biosciences: Non-viral Transfection Reagents Portfolio
Table 12.7 Thermo Fisher Scientific: Company Overview
Table 12.8 Thermo Fisher Scientific: Non-viral Transfection Reagents Portfolio
Table 12.9 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 12.10 BEX: Company Overview
Table 12.11 BEX: Electroporation Systems for Non-viral Transfection
Table 12.12 Bio-Rad Laboratories: Company Overview
Table 12.13 Bio-Rad Laboratories: Electroporation Systems for Non-viral Transfection
Table 12.14 Bio-Rad Laboratories: Recent Developments and Future Outlook
Table 12.15 Harvard Bioscience: Company Overview
Table 12.16 Harvard Bioscience: Electroporation Systems for Non-viral Transfection
Table 12.17 Harvard Bioscience: Recent Developments and Future Outlook
Table 12.18 MaxCyte: Company Overview
Table 12.19 MaxCyte: Electroporation Systems for Non-Viral Transfection
Table 12.20 MaxCyte: Recent Developments and Future Outlook
Table 12.21 Nepa Gene: Company Overview
Table 12.22 Nepa Gene: Electroporation Systems for Non-viral Transfection
Table 12.23 LocateBio: Company Overview
Table 12.24 LocateBio: Non-viral Transfection System / Technology
Table 12.25 N4 Pharma: Company Overview
Table 12.26 N4 Pharma: Non-viral Transfection System / Technology
Table 12.27 N4 Pharma: Recent Developments and Future Outlook
Table 13.1 Most Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in North America
Table 13.2 Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in North America
Table 13.3 Less Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in North America
Table 13.4 Least Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in North America
Table 13.5 Most Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in Europe
Table 13.6 Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in Europe
Table 13.7 Less Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in Europe
Table 13.8 Least Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in Europe
Table 13.9 Most Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in Asia-Pacific and Rest of the World
Table 13.10 Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in Asia-Pacific and Rest of the World
Table 13.11 Less Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in Asia-Pacific and Rest of the World
Table 13.12 Least Likely Partners for Non-Viral Transfection Reagent and System Providers Headquartered in Europe
Table 15.1 Patent Analysis: Top CPC Sections
Table 15.2 Patent Analysis: Top CPC Symbols
Table 15.3 Patent Analysis: Top CPC Codes
Table 15.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 15.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 17.1 Product Price Evaluation Matrix: Based on Transfection Efficiency (USD)
Table 17.2 Product Price Evaluation Matrix: Based on Compatible Cell Type (USD)
Table 17.3 Product Price Evaluation Matrix: Based on Type of Carrier Used (USD)
Table 17.4 Product Price Evaluation Matrix: Based on Type of Molecule Delivered (USD)
Table 17.5 Product Price Evaluation Matrix: Based on Serum Compatibility (USD)
Table 17.6 Product Price Evaluation Matrix: Based on Transfection Efficiency (USD)
Table 17.7 Product Price Evaluation Matrix: Based on Compatible Cell Type
Table 17.8 Product Price Evaluation Matrix: Based on Type of Carrier Used (USD)
Table 17.9 Product Price Evaluation Matrix: Based on Type of Molecule Delivered (USD)
Table 17.10 Product Price Evaluation Matrix: Based on Serum Compatibility (USD)
Table 25.1 Non-Viral Transfection Reagents: Distribution by Compatible Cell Type / Line
Table 25.2 Non-Viral Transfection Reagents: Distribution by Transfected Molecule
Table 25.3 Non-Viral Transfection Reagents: Distribution by Type of Transfection Carrier Used
Table 25.4 Non-Viral Transfection Reagents: Distribution by Type of Cell Culture
Table 25.5 Non-Viral Transfection Reagents: Distribution by Serum Compatibility
Table 25.6 Non-Viral Transfection Reagent Providers: Distribution by Year of Establishment
Table 25.7 Non-Viral Transfection Reagent Providers: Distribution by Company Size
Table 25.8 Non-Viral Transfection Reagent Providers: Distribution by Location of Headquarters
Table 25.9 Electroporation-based Transfection Systems: Distribution by Compatible Cell Type / Line
Table 25.10 Electroporation-based Transfection Systems: Distribution by Transfected Molecule
Table 25.11 Electroporation-based Transfection Systems: Distribution by Type of Waveform
Table 25.12 Electroporation-based Transfection Systems: Cumulative Distribution by Pulse Voltage
Table 25.13 Electroporation-based Transfection System Providers: Distribution by Year of Establishment
Table 25.14 Electroporation-based Transfection System Providers: Distribution by Company Size
Table 25.15 Electroporation-based Transfection System Providers: Distribution by Location of Headquarters
Table 25.16 Leading Players: Number of Electroporation-based Transfection System Offered
Table 25.17 Other Non-Viral Transfection Technology / Systems: Distribution by Type of Offering
Table 25.18 Other Non-Viral Transfection Technology / Systems: Distribution by Compatible Cell Type / Line
Table 25.19 Other Non-Viral Transfection Technology / Systems: Distribution by Transfected Molecule
Table 25.20 Other Non-Viral Transfection Technology / System Providers: Distribution by Year of Establishment
Table 25.21 Other Non-Viral Transfection Technology / System Providers: Distribution by Company Size
Table 25.22 Other Non-Viral Transfection Technology / System Providers: Distribution by Location of Headquarters
Table 25.23 Patent Analysis: Distribution by Type of Patent
Table 25.24 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2022-2025
Table 25.25 Patent Analysis: Cumulative Distribution by Patent and Patent Publication Year, 2022-2025
Table 25.26 Patent Analysis: Cumulative Distribution by Patent Application Year, Pre-2022-2025
Table 25.27 Patent Analysis: Distribution by Patent Jurisdiction
Table 25.28 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2022-2025
Table 25.29 Leading Players: Distribution by Number of Patents
Table 25.30 Leading Inventors: Distribution by Number of Patents
Table 25.31 Patent Analysis: Distribution by Patent Age
Table 25.32 Publication Analysis: Cumulative Year-wise Trend, 2020-2025
Table 25.33 Most Active Publisher: Distribution by Number of Publications
Table 25.34 Key Journals: Distribution by Journal Impact Factor
Table 25.35 Most Popular Journals: Distribution by Number of Publications
Table 25.36 Prominent Copyright Holders: Distribution by Number of Publications
Table 25.37 Global Non-Viral Transfection Reagents and Systems Market, Historical Trends Since 2022 and Forecasted Estimates Till 2035: Base Scenario (USD Billion)
Table 25.38 Global Non-Viral Transfection Reagents and Systems Market, Forecasted Estimates Till 2035: Conservative Scenario (USD Billion)
Table 25.39 Global Non-Viral Transfection Reagents and Systems Market, Forecasted Estimates Till 2035: Optimistic Scenario (USD Billion)
Table 25.40 Non-Viral Transfection Reagents and Systems Market: Distribution by Type of Transfected Method
Table 25.41 Non-Viral Transfection Reagents and Systems Market for Chemical Methods, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.42 Non-Viral Transfection Reagents and Systems Market for Physical Methods, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.43 Non-Viral Transfection Reagents and Systems Market for Other Methods, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.44 Non-Viral Transfection Reagents and Systems Market: Distribution by Application Area
Table 25.45 Non-Viral Transfection Reagents and Systems Market for Research Applications, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.46 Non-Viral Transfection Reagents and Systems Market for Clinical Applications, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.47 Non-Viral Transfection Reagents and Systems Market: Distribution by End-Users
Table 25.48 Non-Viral Transfection Reagents and Systems Market for Academic and Research Institutes, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.49 Non-Viral Transfection Reagents and Systems Market for Pharmaceutical and Biopharmaceutical Companies, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.50 Non-Viral Transfection Reagents and Systems Market for Contract Manufacturers, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.51 Non-Viral Transfection Reagents and Systems Market for Other End-Users, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.52 Non-Viral Transfection Reagents and Systems Market: Distribution by Geographical Regions
Table 25.53 Non-Viral Transfection Reagents and Systems Market in North America, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.54 Non-Viral Transfection Reagents and Systems Market in the US, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.55 Non-Viral Transfection Reagents and Systems Market in Canada, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.56 Non-Viral Transfection Reagents and Systems Market in Europe, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.57 Non-Viral Transfection Reagents and Systems Market in Germany, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.58 Non-Viral Transfection Reagents and Systems Market in France, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.59 Non-Viral Transfection Reagents and Systems Market in the UK, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.60 Non-Viral Transfection Reagents and Systems Market in Italy, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.61 Non-Viral Transfection Reagents and Systems Market in Spain, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.62 Non-Viral Transfection Reagents and Systems Market in Rest of Europe, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.63 Non-Viral Transfection Reagents and Systems Market in Asia-Pacific, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.64 Non-Viral Transfection Reagents and Systems Market in Japan, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.65 Non-Viral Transfection Reagents and Systems Market in Australia, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.66 Non-Viral Transfection Reagents and Systems Market in South Korea, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.67 Non-Viral Transfection Reagents and Systems Market in China, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.68 Non-Viral Transfection Reagents and Systems Market in Rest of Asia-Pacific, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.69 Non-Viral Transfection Reagents and Systems Market in Middle East and Africa, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.70 Non-Viral Transfection Reagents and Systems Market in Saudi Arabia, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.71 Non-Viral Transfection Reagents and Systems Market in UAE, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.72 Non-Viral Transfection Reagents and Systems Market in Egypt, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.73 Non-Viral Transfection Reagents and Systems Market in Rest of Middle East and Africa, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.74 Non-Viral Transfection Reagents and Systems Market in Latin America, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.75 Non-Viral Transfection Reagents and Systems Market in Brazil, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.76 Non-Viral Transfection Reagents and Systems Market in Argentina, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 25.77 Non-Viral Transfection Reagents and Systems Market in Rest of Latin America, Forecasted Estimates Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Commonly Used Viral Vectors
Figure 6.2 Types of Non-Viral Transfection Methods
Figure 6.3 Electroporation Mechanism
Figure 6.4 Gene Gun Mechanism
Figure 6.5 Sonoporation Mechanism
Figure 6.6 Microinjection Mechanism
Figure 6.7 Magnetofection Mechanism
Figure 6.8 Applications of Transfection
Figure 7.1 Non-viral Transfection Reagents: Distribution by Compatible Cell Type / Line
Figure 7.2 Non-Viral Transfection Reagents: Distribution by Transfected Molecule
Figure 7.3 Non-Viral Transfection Reagents: Distribution by Type of Transfection Carrier Used
Figure 7.4 Non-Viral Transfection Reagents: Distribution by Type of Cell Culture
Figure 7.5 Non-Viral Transfection Reagents: Distribution by Serum Compatibility
Figure 7.6 Non-Viral Transfection Reagent Providers: Distribution by Year of Establishment
Figure 7.7 Non-Viral Transfection Reagent Providers: Distribution by Company Size
Figure 7.8 Non-Viral Transfection Reagent Providers: Distribution by Location of Headquarters
Figure 8.1 Electroporation-based Transfection Systems: Distribution by Compatible Cell Type / Line
Figure 8.2 Electroporation-based Transfection Systems: Distribution by Transfected Molecule
Figure 8.3 Electroporation-based Transfection Systems: Distribution by Type of Waveform
Figure 8.4 Electroporation-based Transfection Systems: Cumulative Distribution by Pulse Voltage
Figure 8.5 Electroporation-based Transfection System Providers: Distribution by Year of Establishment
Figure 8.6 Electroporation-based Transfection System Providers: Distribution by Company Size
Figure 8.7 Electroporation-based Transfection System Providers: Distribution by Location of Headquarters
Figure 8.8 Leading Players: Distribution by Number of Electroporation-based Transfection Systems Offered
Figure 9.1 Other Non-Viral Transfection Technologies / Systems: Distribution by Type of Offering
Figure 9.2 Other Non-Viral Transfection Technologies / Systems: Distribution by Compatible Cell Type / Line
Figure 9.3 Other Non-Viral Transfection Technology / Systems: Distribution by Transfected Molecule
Figure 9.4 Other Non-Viral Transfection Technology / System Providers: Distribution by Year of Establishment
Figure 9.5 Other Non-Viral Transfection Technology / System Providers: Distribution by Company Size
Figure 9.6 Other Non-Viral Transfection Technology / System Providers: Distribution by Location of Headquarters
Figure 10.1 Company Competitiveness Analysis: Non-Viral Transfection Reagent Providers based in North America (Peer Group I)
Figure 10.2 Company Competitiveness Analysis: Non-Viral Transfection Reagent Providers based in Europe (Peer Group II)
Figure 10.3 Company Competitiveness Analysis: Non-Viral Transfection Reagent Providers based in Asia-Pacific (Peer Group III)
Figure 11.1 Electroporation-based Systems: Distribution of Technologies Offered by Players based in North America (Peer Group Ia)
Figure 11.2 Electroporation-based Systems Distribution of Technologies Offered by Players based in Europe and Asia-Pacific (Peer Group Ib)
Figure 11.3 Other Non-Viral Transfection Technologies / Systems: Distribution of Technologies Offered by Players based in North America (Peer Group IIa)
Figure 11.4 Other Non-Viral Transfection Technologies / Systems: Distribution of Technologies Offered by Players based in Europe and Asia-Pacific (Peer Group IIb)
Figure 12.1 MilliporeSigma: Annual Revenues(EUR Billion)
Figure 12.2 Thermo Fisher Scientific: Business Segment-wise Annual Revenues(USD Billion)
Figure 12.3 Bio-Rad Laboratories: Business Segment-wise Annual Revenues(USD Million)
Figure 12.4 Harvard Bioscience: Business Segment-wise Annual Revenues(USD Million)
Figure 12.5 MaxCyte: Business Segment-wise Annual Revenues(USD Billion)
Figure 15.1 Patent Analysis: Distribution by Type of Patent
Figure 15.2: Patent Analysis: Cumulative Distribution by Patent Publication Year, 2022-2025
Figure 15.3 Patent Analysis: Distribution by Type of Patent and Publication Year, 2022-2025
Figure 15.4 Patent Analysis: Distribution by Patent Application Year, Pre-2022-2025
Figure 15.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 15.6 Patent Analysis: Distribution by CPC Symbols
Figure 15.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2022-2025
Figure 15.8 Leading Players: Distribution by Number of Patents
Figure 15.9 Leading Inventors: Distribution by Number of Patents
Figure 15.10 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Players
Figure 15.11 Patent Benchmarking Analysis: Distribution of Leading Players by Patent Characteristics (CPC Codes)
Figure 15.12 Patent Analysis: Distribution by Patent Age
Figure 15.13 Non-Viral Transfection: Patent Valuation
Figure 16.1 Publication Analysis: Cumulative Year-wise Trend, 2020-2025
Figure 16.2 Most Active Publisher: Distribution by Number of Publication
Figure 16.3 Key Journals: Distribution by Journal Impact Factor
Figure 16.4 Most Popular Journals: Distribution by Number of Publications
Figure 16.5 Prominent Copyright Holders: Distribution by Number of Publications
Figure 17.1 Non-Viral Transfection Reagents: Roots Analysis Pricing Strategy Graphical Interpretation
Figure 17.2 Non-Viral Transfection Reagents: Roots Analysis Pricing Strategy Graphical Interpretation
Figure 19.1 Global Non-Viral Transfection Reagents and Systems Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.2 Global Non-Viral Transfection Reagents and Systems Market, Forecasted Estimates Till 2035, Conservative Scenario (USD Billion)
Figure 19.3 Global Non-Viral Transfection Reagents and Systems Market, Forecasted Estimates Till 2035, Optimistic Scenario (USD Billion)
Figure 20.1 Non-Viral Transfection Reagents and Systems Market: Distribution by Type of Transfection Method
Figure 20.2 Non-Viral Transfection Reagents and Systems Market for Chemical Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.3 Non-Viral Transfection Reagents and Systems Market for Physical Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.4 Non-Viral Transfection Reagents and Systems Market for Other Methods, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.1 Non-Viral Transfection Reagents and Systems Market: Distribution by Application Area
Figure 21.2 Non-Viral Transfection Reagents and Systems Market for Research Applications, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.3 Non-Viral Transfection Reagents and Systems Market for Clinical Applications, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.1 Non-Viral Transfection Reagents and Systems Market: Distribution by End-User
Figure 22.2 Non-Viral Transfection Reagents and Systems Market for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.3 Non-Viral Transfection Reagents and Systems Market for Pharmaceutical and Biopharmaceutical Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.4 Non-Viral Transfection Reagents and Systems Market for Contract Manufacturers, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.5 Non-Viral Transfection Reagents and Systems Market for Other End-Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.1 Non-Viral Transfection Reagents and Systems Market: Distribution by Geographical Regions
Figure 23.2 Non-Viral Transfection Reagents and Systems Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.3 Non-Viral Transfection Reagents and Systems Market in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.4 Non-Viral Transfection Reagents and Systems Market in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.5 Non-Viral Transfection Reagents and Systems Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.6 Non-Viral Transfection Reagents and Systems Market in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.7 Non-Viral Transfection Reagents and Systems Market in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.8 Non-Viral Transfection Reagents and Systems Market in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.9 Non-Viral Transfection Reagents and Systems Market in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.10 Non-Viral Transfection Reagents and Systems Market in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.11 Non-Viral Transfection Reagents and Systems Market in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.12 Non-Viral Transfection Reagents and Systems Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.13 Non-Viral Transfection Reagents and Systems Market in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.14 Non-Viral Transfection Reagents and Systems Market in Australia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.15 Non-Viral Transfection Reagents and Systems Market in South Korea, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.16 Non-Viral Transfection Reagents and Systems Market in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.17 Non-Viral Transfection Reagents and Systems Market in Rest of Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.18 Non-Viral Transfection Reagents and Systems Market in Middle East and Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.19 Non-Viral Transfection Reagents and Systems Market in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.20 Non-Viral Transfection Reagents and Systems Market in UAE, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.21 Non-Viral Transfection Reagents and Systems Market in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.22 Non-Viral Transfection Reagents and Systems Market in Rest of Middle East and Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.23 Non-Viral Transfection Reagents and Systems Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.24 Non-Viral Transfection Reagents and Systems Market in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.25 Non-Viral Transfection Reagents and Systems Market in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.26 Non-Viral Transfection Reagents and Systems Market in Rest of Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.27 Market Movement Analysis: Geographical Regions
Figure 23.28 Penetration-Growth (P-G) Matrix: Geographical Regions
Figure 24.1 Concluding Remarks: Overall Market Landscape of Non-Viral Transfection Reagents
Figure 24.2 Concluding Remarks: Overall Market Landscape of Electroporation-based Non-Viral Transfection Systems
Figure 24.3 Concluding Remarks: Overall Market Landscape of Other Non-Viral Transfection Technologies / Systems
Figure 24.4 Concluding Remarks: Patent Analysis
Figure 24.5 Concluding Remarks: Market Sizing and Opportunity Analysis
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們